BG61366B2 - Използване на съединения на метокси алифатните киселини с индазол за получаване на фармацевтично средство за лечение на автоимунни заболявания - Google Patents

Използване на съединения на метокси алифатните киселини с индазол за получаване на фармацевтично средство за лечение на автоимунни заболявания Download PDF

Info

Publication number
BG61366B2
BG61366B2 BG98590A BG9859094A BG61366B2 BG 61366 B2 BG61366 B2 BG 61366B2 BG 98590 A BG98590 A BG 98590A BG 9859094 A BG9859094 A BG 9859094A BG 61366 B2 BG61366 B2 BG 61366B2
Authority
BG
Bulgaria
Prior art keywords
compound
formula
autoimmune
preparation
treatment
Prior art date
Application number
BG98590A
Other languages
Bulgarian (bg)
English (en)
Inventor
Bruno Silvestrini
Original Assignee
Angelini Ricerche S.P.A. Societa'consortile
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Angelini Ricerche S.P.A. Societa'consortile filed Critical Angelini Ricerche S.P.A. Societa'consortile
Publication of BG61366B2 publication Critical patent/BG61366B2/bg

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Reproductive Health (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
BG98590A 1991-04-22 1994-02-25 Използване на съединения на метокси алифатните киселини с индазол за получаване на фармацевтично средство за лечение на автоимунни заболявания BG61366B2 (bg)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ITMI911101A IT1253703B (it) 1991-04-22 1991-04-22 Uso di acidi metossi alcanoici dell'indazolo per preparare un farmaco attivo nel trattamento di malattie autoimmunitarie

Publications (1)

Publication Number Publication Date
BG61366B2 true BG61366B2 (bg) 1997-06-30

Family

ID=11359721

Family Applications (1)

Application Number Title Priority Date Filing Date
BG98590A BG61366B2 (bg) 1991-04-22 1994-02-25 Използване на съединения на метокси алифатните киселини с индазол за получаване на фармацевтично средство за лечение на автоимунни заболявания

Country Status (16)

Country Link
US (1) US5278183A (fr)
EP (1) EP0510748B1 (fr)
JP (1) JP3056879B2 (fr)
KR (1) KR100210199B1 (fr)
AT (1) ATE135573T1 (fr)
AU (1) AU657524B2 (fr)
BG (1) BG61366B2 (fr)
CA (1) CA2066304C (fr)
CZ (1) CZ280613B6 (fr)
DE (1) DE69209128T2 (fr)
DK (1) DK0510748T3 (fr)
IL (1) IL101660A (fr)
IT (1) IT1253703B (fr)
NZ (1) NZ242392A (fr)
SK (1) SK278546B6 (fr)
ZA (1) ZA922740B (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2723315B1 (fr) * 1994-08-02 1996-10-25 Cird Galderma Procede et composition pour stimuler la differenciation des cellules preadipocytaires et traitements therapeutiques associes
IT1276031B1 (it) * 1995-10-31 1997-10-24 Angelini Ricerche Spa Composizione farmaceutica per il trattamento delle malattie autoimmuni
IT1293795B1 (it) 1997-07-28 1999-03-10 Angelini Ricerche Spa Farmaco attivo nel ridurre la produzione di proteina mcp-1
EP1448557A4 (fr) * 2001-10-26 2005-02-02 Univ Connecticut Heteroindanes: nouvelle classe de ligands cannabimimetiques efficaces
ITMI20062254A1 (it) 2006-11-24 2008-05-25 Acraf Uso di un acido metossi-alcanoico dell'indazolo per preparare una composizione farmaceutca
AU2009221063B2 (en) 2008-03-07 2013-03-21 Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.P.A. 1-benzyl-3-hydroxymethylindazole derivatives and use thereof in the treatment of diseases based on the expression of MCP-1, and CX3CR1
LT2254869T (lt) 2008-03-07 2017-08-10 Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.P.A. Nauji 1-benzil-3-hidroksimetilindazolo dariniai ir jų panaudojimas gydyme ligų, susijusių su cx3cr1 ir p40 raiška
US8461194B2 (en) 2008-03-07 2013-06-11 Aziende Chimiche Riunite Angelini Francesco A. C. R. A. F. S. P. A. 1-benzyl-3-hydroxymethylindazole derivatives and use thereof in the treatment of diseases based on the expression of MCP-1, CX3CR1 and P40
MX2012001520A (es) 2009-08-03 2012-06-01 Acraf Proceso para la preparacion de 1-bencil-3-hidroximetil-1h-indazol y sus derivados e intermediarios de magnesio requeridos.
UA108742C2 (uk) * 2009-09-23 2015-06-10 Фармацевтична композиція для лікування запальних захворювань, опосередкованих mcp-1
US8999292B2 (en) 2012-05-01 2015-04-07 Translatum Medicus Inc. Methods for treating and diagnosing blinding eye diseases
WO2020261158A1 (fr) 2019-06-25 2020-12-30 Translatum Medicus Inc. Procédés de fabrication d'acide 2-((1-benzyl-1h-indazol-3-yl)méthoxy)-2-méthylpropanoïque et de ses dérivés

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1194564B (it) * 1983-04-18 1988-09-22 Acraf Impiego del bendazac e dei suoi sali nel trattamento della retinite pigmentosa
EP0191520B1 (fr) * 1985-02-12 1989-06-21 AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.p.A. Acide(phénylméthyl-1 hydroxy-5 1H-indazolyl-3)oxyacétique et ses sels utiles comme médicaments et compositions pharmaceutiques les contenant
IT1230441B (it) * 1989-02-07 1991-10-23 Acraf Eteri della serie dell'indazolo

Also Published As

Publication number Publication date
EP0510748A1 (fr) 1992-10-28
CS122792A3 (en) 1992-11-18
CA2066304C (fr) 2005-06-21
NZ242392A (en) 1997-06-24
IL101660A (en) 1996-08-04
CA2066304A1 (fr) 1992-10-23
IT1253703B (it) 1995-08-23
ATE135573T1 (de) 1996-04-15
DE69209128D1 (de) 1996-04-25
AU1488392A (en) 1992-10-29
SK278546B6 (en) 1997-09-10
ITMI911101A1 (it) 1992-10-22
KR920019350A (ko) 1992-11-19
ITMI911101A0 (it) 1991-04-22
DK0510748T3 (da) 1996-07-22
JPH0640915A (ja) 1994-02-15
DE69209128T2 (de) 1996-11-28
KR100210199B1 (ko) 1999-07-15
CZ280613B6 (cs) 1996-03-13
AU657524B2 (en) 1995-03-16
ZA922740B (en) 1992-12-30
US5278183A (en) 1994-01-11
EP0510748B1 (fr) 1996-03-20
JP3056879B2 (ja) 2000-06-26

Similar Documents

Publication Publication Date Title
KR100464693B1 (ko) 5-메틸이소옥사졸-4-카복실산-(4-트리플루오로메틸)-아닐리드와n-(4-트리플루오로메틸페닐)-2-시아노-3-하이드록시크로톤산아미드와의배합물을함유하는제제
BG61366B2 (bg) Използване на съединения на метокси алифатните киселини с индазол за получаване на фармацевтично средство за лечение на автоимунни заболявания
EP0001727B1 (fr) Nouveaux dérivés du phényl-4-(trichloro-2',2',2'-éthoxycarboxamido)-2-thiazole utiles comme médicaments, compositions pharmaceutiques les contenant et leur procédé de préparation
KR20140035538A (ko) 선별적 ｓ1ｐ₁ 수용체 작동약에 대한 투약 섭생
US20060173011A1 (en) Treatment of inflammatory disorders with praziquantel
KR20080098494A (ko) 염증 질환 치료를 위한 ｇａｂａａ-활성화된 신경전달을 증진시키는 화합물의 용도
WO2019209738A1 (fr) Utilisation d'inhibiteurs d'élastase neutrophile dans une maladie hépatique
CN1477957A (zh) 用于治疗高血氨症及肝性脑病的含二氢呋喃环结构的丹参酮类化合物
US20050070565A1 (en) Chelerythrine, analogs thereof and their use in the treatment of bipolar disorder and other cognitive disorders
Wurtman et al. Dietary enhancement of CNS neurotransmitters
RU2160102C2 (ru) Применение бензидамина для лечения патологических состояний, вызванных фно
KR100286141B1 (ko) 6,7-치환-2-아미노테트랄린을 함유한 패혈성 쇼크 치료용 및 해열, 소염용 의약 조성물
US4880803A (en) Method of inducing immunostimulating activity
US4478845A (en) Antiinflammatory and/or analgesic imidazoimidazoles
US3906107A (en) Aminoalkyl sulfate esters with diuretic activity
US3624202A (en) Process for stilling pain
Austin et al. Rate of formation of norpethidine from pethidine
EA000166B1 (ru) Биологически активные уреидо-производные, полезные при лечении рассеянного склероза
HU219406B (hu) Eljárás autoimmun betegségek kezelésére alkalmas, benzil-indazol-származékokat tartalmazó gyógyszerkészítmények előállítására
Lassen et al. Potentiation of nialamide-induced hypermotility in mice by lithium and the 5-HT uptake inhibitors chlorimipramine and FG 4963
Beck et al. Cortical EEG stimulant effects in the rabbit of acetaldehyde-biogenic amine reaction products
JPS62198616A (ja) 脳血流量改善・脳細胞保護剤
US4721714A (en) Anti-vertigo drug
KR20010041967A (ko) 뇌조직 장애를 예방 및 치료하기 위한 시스테인프로테아제 억제제 함유 약제학적 조성물
Leonards et al. Effect of Penicillin on Blood Urea in the Rat